Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma
NCT ID: NCT01366157
Last Updated: 2016-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
23 participants
OBSERVATIONAL
2011-05-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial is studying protein biomarker levels in tissue samples from young patients with low-risk Hodgkin lymphoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors
NCT00001301
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma
NCT01490801
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma
NCT00900250
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
NCT02856646
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00720135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To investigate the variability of expression of human geminal-center-associated lymphoma (HGAL) protein in pediatric low-risk Hodgkin lymphoma.
* To assess the variability of HGAL staining between risk groups by comparing samples from subjects enrolled in the low-risk study AHOD0431 with subject samples enrolled in AHOD0031 for intermediate-risk classical Hodgkin Lymphoma (cHL).
* To assess the variability of HGAL staining by evaluating a tissue array created from subjects with intermediate-risk cHL.
* To correlate rapid or slow early-response in the intermediate-risk group with HGAL protein expression.
OUTLINE: Paraffin-embedded tissue samples and tissue microarrays are analyzed for protein expression by IHC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
microarray analysis
protein expression analysis
immunohistochemistry staining method
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with low-risk classical Hodgkin lymphoma (cHL)
* Samples available from patients enrolled in the low-risk study COG-AHOD0431 and in the intermediate-risk cHL study COG-AHOD0031
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frank G. Keller, MD
Role: PRINCIPAL_INVESTIGATOR
Emory Children's Center - Atlanta
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AHOD11B1
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000701020
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02859
Identifier Type: REGISTRY
Identifier Source: secondary_id
AHOD11B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.